Intra-Cellular Therapies Skyrockets 34% Amid High Volume, Bucking Market Trends

1. Nvidia (Nasdaq: NVDA)
Nvidia dipped mildly by -1.97%, with the trading volume of 26.67B. NVIDIA opposes the Biden administration's new AI chip export restrictions, potentially impacting U.S. global competitiveness. Nvidia announced cooperation with Illumina and Mayo Clinic to advance AI in healthcare. Meanwhile, HSBC maintains its buy rating for NVIDIA with a target price of $185.00.

2. Tesla (Nasdaq: TSLA)
Tesla gained mildly by 2.17%, with the trading volume of 25.64B. Tesla's Austin plant adjusts production lines as Cybertruck deliveries fall short. Tesla launches a redesigned Model Y with a new front bumper camera. A large European pension fund reduces Tesla holdings. Morgan Stanley maintains an overweight rating, raising the target price to $430.

3. Apple (Nasdaq: AAPL)
Apple dipped mildly by -1.03%, with the trading volume of 11.52B. Apple plans to launch a budget iPhone model soon, while its smartphone shipments in China are declining, affecting 2025 sales prospects. Meanwhile, Apple's modified app developer fee structure faces scrutiny from EU regulators.

4. Microsoft (Nasdaq: MSFT)
Microsoft dipped mildly by -0.42%, with the trading volume of 7.30B. Microsoft has launched a new AI engineering division led by Jay Parikh as Executive Vice President. Additionally, Microsoft is investigating issues with its multi-factor authentication affecting Microsoft 365 access, with redirected traffic reportedly improving service availability.

5. Meta Platforms (Nasdaq: META)
Meta Platforms dipped mildly by -1.22%, with the trading volume of 6.46B. Meta faces a lawsuit after the U.S. Supreme Court declined to hear its appeal against advertisers' claims of overstated ad reach. Wells Fargo maintains an Overweight rating for Meta with a $685 target price. CEO Mark Zuckerberg predicts AI programming advancements by 2025.

6. Amazon (Nasdaq: AMZN)
Amazon.Com dipped mildly by -0.22%, with the trading volume of 5.91B. Amazon is set to shut down its Prime Try Before You Buy service on January 31, 2025, replacing it with AI features. The company is also halting some Diversity, Equity, and Inclusion programs, reviewing multiple initiatives. Jeff Bezos assured that Elon Musk won't misuse power against Blue Origin.

7. Broadcom (Nasdaq: AVGO)
Broadcom gained mildly by 0.44%, with the trading volume of 5.33B. Broadcom experienced a significant transaction value on January 13, 2025, and saw its stock decline over 2% amid a broader drop in semiconductor stocks following new AI chip export restrictions. Additionally, a company director sold 96,000 shares in a single day.

8. Microstrategy Incorporated (Nasdaq: MSTR)
Microstrategy Incorporated gained mildly by 0.15%, with the trading volume of 4.99B. Microstrategy plans to increase its Bitcoin holdings, with the company reaffirming its commitment to cryptocurrency as part of its strategic growth initiative.

9. Intra-Cellular Therapies (Nasdaq: ITCI)
Intra-Cellular Therapies surged by 34.07%, with the trading volume of 4.57B. Intra-cellular's rating was downgraded by Needham from buy to hold, with a new target price of $100. The company reported Q3 2024 earnings on October 30, with revenue figures as of September 30, 2024.

10. Advanced Micro Devices (Nasdaq: AMD)
Advanced Micro Devices gained mildly by 1.10%, with the trading volume of 4.48B. Wells Fargo maintains Advanced Micro Devices (AMD) rating at overweight with a target price of $165. AMD reported Q3 2024 revenue of $181.27 billion and net profit of $11.59 billion. AMD announced new Radeon RX 9070 XT and RX 9070 graphics cards at CES 2025.